President Trump announced deals with pharmaceutical companies Novo Nordisk and Eli Lilly that will cut the cost of weight loss drugs.
The agreement represents a “historic reduction in prices for Americans on the two drugs with the highest annual expenditures in the United States, both of which help adults struggling with diabetes, heart disease (Ozempic and Wegovy only), obesity, and other conditions,” a White House fact sheet says.
The prices of Ozempic and Wegovy will fall to $350 when purchased through TrumpRx. Prices of Zepbound and Orforglipron will fall to an average of $346.
Furthermore, the agreement guarantees that Eli Lilly and Novo Nordisk will provide “MFN prices on all new medicines that they bring to market, repatriate increased foreign revenue on existing products, and provide every State Medicaid program in the country access to MFN drug prices on their products.”
Other medications, such as Emgality, Trulicity, NovoLog, and Tresiba, will also see reduced pricing.
Eli Lilly Chair and CEO David Ricks said the agreement is a “pivotal moment in U.S. health care policy and a defining milestone for Lilly, made possible through collaboration with the Trump Administration.”
The Trump administration announced in September that it reached a deal with Pfizer to lower drug prices.
A fact sheet explains the agreement will provide “every State Medicaid program in the country access to [most-favored-nation] drug prices on Pfizer products” and “ensures foreign nations can no longer use price controls to freeride on American innovation by guaranteeing MFN prices on all new innovative medicines Pfizer brings to market.”
Amgen also announced that it will offer discounted, direct-to-consumer sales of the injectable drug Repatha, which is used to treat high cholesterol.
